Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies

Journal of Virology

Volumn 70, Issue 8, 1996, Pages 5357-5362

  Khanna, Rajiv ^a   Burrows, Scott R ^a   Moss, Denis J ^a   Silins, Sharon L ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN;

ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ARTICLE; B LYMPHOCYTE ACTIVATION; CARCINOGENESIS; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; EPSTEIN BARR VIRUS; HERPES VIRUS INFECTION; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; NASOPHARYNX CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEIN TRANSPORT; VACCINIA VIRUS; VIRUS RESISTANCE;

EID: 0030013725     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/jvi.70.8.5357-5362.1996     Document Type: Article

References (47)

1. Anderson, K., P. Cresswell, M. Gammon, J. Hermes, A. Williaimon, and H. Zweerink. 1991. Endogenously synthesized peptide with an endoplasmic reticulum signal sequence sensitizes antigen processing mutant cells to class I-restricted cell-mediated lysis. J. Exp. Med. 174:489-492.
2. Azuma, M., M. Cayabyab, U. Buck, J. H. Phillips, and L, L. Lanier. 1992. CD28 interaction with B7 costimulates primary allogeneic proliferative responses and cytotoxicity mediated by small, resting T lymphocytes. J. Exp. Med. 175:353-360.
3. Bacik, I., J. H. Cox, R. Anderson, J. W. Yewdell, and J. R. Bennink. 1994. TAP (transporter associated with antigen processing)-independent presentation of endogenously synthesized peptides is enhanced by endoplasmic reticulum insertion sequences located at the amino - but not carboxyl - terminus of the peptide. J. Immunol. 152:381-387.
4. Baskar, S., S. Ostrand Rosenberg, N. Nabavi, L. M. Nadler, G. J. Freeman, and L. H. Glimcher. 1993. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated major histocompatibility complex class II molecules. Proc. Natl. Acad. Sci. USA 90:5687-5690.
5. Braciale, T. J., and V. L. Braciale. 1991. Antigen presentation: structural themes and functional variations. Immunol. Today 12:124-129.
6. Browning, M. J., and W. F. Bodmer. 1992. MHC antigens and cancer: implications for T-cell surveillance. Curr. Opin. Immunol. 4:613-618.
7. Burrows, S. R., J. Gardner, R. Khanna, T. Steward, D. J. Moss, S. Rodda, and A, Suhrbier. 1994. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3. J. Gen. Virol. 75:2489-2493.
8. Burrows, S. R., S. J. Rodda, A. Suhrbier, H. M. Geysen, and D. J. Moss. 1992. The specificity of recognition of a cytotoxic T lymphocyte epitope. Eur. J. Immunol. 22:191-195.
9. Busch, R., I. Y. Vturina, J. Drexler, F. Momburg, and G. J. Hammerling. 1995. Poor loading of major histoeompatibility complex class II molecules with endogenously synthesized short peplides in the absence of invariant chains. Eur. J. Immunol. 25:48-53.
10. Busson, P., R. McCoy, R. Sadler, K. Gilligan, T. Tursz, and N. Raab-Traub. 1992. Consistent transcription of the Epstein-Barr virus LMP2 gene in nasopharyngeal carcinoma. J. Virol. 66:3257-3262.
11. Cromme, F. V., P. F. van Bommel, J. M. Walboomers, M. P. Gallee, P. L. Stern, P. Kenemans, T. J. Helmerhorst, M. J. Stukart, and C. J. Meijer. 1994. Differences in MHC and TAP-1 expression in cervical cancer lymph node metastases as compared with the primary tumours. Br. J. Cancer 69:1176-1181.
12. Deacon, E. M., G. Pallesen, G. Niedobitek, J. Crocker, L, Brooks, A. B. Rickinson, and L. S. Young. 1993. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J. Exp. Med. 177:339-349.
13. Hammond, S. A., R. C. Bollinger, T. W. Tobery, and R. F. Siliciano. 1993. Transporter-independent processing of HIV-1 envelope protein for recognition by CD8+ T-cells. Nature (London) 364:158-161.
14. Hammond, S. A., R. P. Johnson, S. A. Kalams, B. D. Walker, M. Takiguchi, J. T. Safrit, R. A. Koup, and R. F. Siliciano. 1995. An epitope-selective, transporter associated with antigen presentation (TAP)-1/2-independent pathway and a more general TAP-1/2-dependent antigen-processing pathway allow recognition of the HIV-1 envelope glycoprotein by CD8+ CTL. J. Immunol. 154:6140-6156.
15. Henderson, R. A., H. Michel, K. Sakaguchi, J. Shabanowitz, E. Appells, D. F. Hunt, and V. H. Engelhard. 1992. HLA-A2.1-associated peptides from a mutant-cell line: a second pathway of antigen presentation. Science 255: 1264-1266.
16. Hill, A., A. Worth, T. Elliott, S. Rowland-Jones, J. Brooks, A. Rickinson, and A. McMichael. 1995. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7. Eur. J. Immunol. 25:18-24.
17. Hu, L. F., J. Minarovils, S. L. Cao, B. Contreras-Salazar, L. Rymo, K. Falk, G. Klein, and I. Ernberg. 1991. Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5′-flanking region. J. Virol. 65:1558-1567.
18. Kast, W. M., L. Roux, J. Curren, H. J. Blom, A. C. Voordouw, and R. H. Meloen. 1991. Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad. Sci. USA 88:2283-2287.
19. Khanna, R., S. R. Burrows, V. Argaet, and D. J. Moss. 1994. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line. Int. Immunol. 6:639-645.
20. Khanna, R., S. R. Burrows, M. G. Kurilla, C. A. Jacob, I. S. Misko, T. B. Sculley, E. Kieff, and D. J. Moss. 1992. Localization of Epstein-Barr virus cytotoxic T-cell epitopes using recombinant vaccinia: implications for vaccine development. J. Exp. Med. 176:169-176.
21. Khanna, R., S. R. Burrows, A. Suhrbier, C. A. Jacob, H. Grifin, I. S. Misko, T. B. Sculley, M. Rowe, A. B. Rickinson, and D. J. Moss, 1993. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2. J. Immunol. 150: 5154-5162.
22. Khanna, R., C. A. Jacob, S. R. Burrows, M. G. Kurilla, E. Kieff, I. S. Misko, and D. J. Moss. 1991. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T-cells. Immunology 74:504-510.
23. Khanna, R., C. A. Jacob, S. R. Burrows, and D. J. Moss. 1993. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection. J. Immunol. Methods 164:41-49.
24. Knecht, H., E. Bachmann, F. Brousset, K. Sandvej, D. Nadal, F. Bachmann, B. F. Odermatt, G. Delsol, and G. Pallesen. 1993. Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood 82:2937-2942.
25. Lee, S. P., W. A. Thomas, R. J. Murray, F. Khanim, S. Kaur, L. S. Young, M. Rowe, M. Kurilla, and A. B. Rickinson. 1993. HLA A2. 1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane antigen. J. Virol. 67:7428-7435.
26. Lobigs, M., and A. Mullbacher. 1995. Recombinant expression of vaccinia virus-encoded TAP1 and TAP2 promotes MHC class I-restricted antigen presentation in a Syrian hamster cell line. Immunol. Cell Biol. 73:181-184.
27. Longnecker, R., and E. Kieff. 1990. A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1. J. Virol. 64:2319-2326.
28. Moss, D. J., I. S. Misko, S. K. Burrows, K. Burman, R. McCarthy, and T. B. Sculley. 1988. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants. Nature (London) 331:719-721.
29. Pardoll, D. 1992. Immunotherapy with cytokine gene-transduced tumor cells: the next wave in gene therapy for cancer. Curr. Opin. Oncol. 4:1124-1129.
30. Powis, S. J., A. R. Townsend, E. V. Deverson, J. Bastin, G. W. Butcher, and J. C. Howard. 1991. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter. Nature (London) 354:528-531.
31. Prehn, R. T., and J. M. Main. 1957. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 18:769.
32. Restifo, N. P., F. Esquivel, V. Kawakami, J. W. Yewdell, J. J. Mule, S. A. Rosenberg, and J. R. Bennink. 1993. Identification of human cancers deficient in antigen processing. J. Exp. Med. 177:265-272.
33. Rickinson, A. B., R. J. Murray, J. Brooks, H. Griffin, D. J. Moss, and M. G. Masucci. 1992. T cell recognition of Epstein-Barr virus associated lymphomas. Cancer Surv. 13:53-80.
34. Rooney, C. M., A. B. Rickinson, D. J. Moss, G. M. Lenoir, and M. A. Epstein. 1985. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma. IARC Sci. Publ. 60:249-264.
35. Rose, J. K., and R. W. Doms. 1988. Regulation of protein export from the endoplasmic reticulum. Annu. Rev. Cell Biol. 4:257-288.
36. Rosenberg, S. A.,E. A. Grimm, M. McGrogan, M. Doyle, E. Kawasaki, K. Koths, and D. F. Mark. 1984. Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science 223:1412-1414.
37. Rowe, M., R. Khanna, C. A. Jacob, V. Argaet, A. Kelly, S. Powis, M. Belich, D. Croom Carter, S. Lee, S. R. Burrows, D. J. Moss, and A. B. Rickinson. 1995. Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur. J. Immunol. 25:1374-1384.
38. Salter, R. D., and P. Cresswell. 1986. Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. EMBO J. 5:943-949.
39. Slingluff, C. L., Jr., D. F. Hunt, and V. H. Engelhard. 1994. Direct analysis of tumor-associated peptide antigens. Curr. Opin. Immunol. 6:733-740.
40. Snyder, H. L., J. W. Yewdell, and J. R. Bennink. 1994. Trimming of antigenic peptides in an early secretory compartment. J. Exp. Med. 180:2389-2394.
41. Spies, T., M. Bresnahan, S. Bahram, D. Arnold, G. Blanck, and E. Meltins. 1990. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway. Nature (London) 348: 744-747.
42. Spies, T., and R, DeMars. 1991. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter. Nature (London) 351:323-324.
43. Trowsdale, J., I. Hanson, I. Mockridge, S. Beck, A. Townsend, and A. Kelly. 1990. Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature (London) 348:741-744.
44. van der Bruggen, P., C. Traversari, P. Chomez, C. Lurquin, E. De Plaen, B. Van den Eynde, A. Knuth, and T. Boon. 1991. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 254: 1643-1647.
45. Wei, M. L., and P. Cresswell. 1992. HLA-A2 molecules in an antigen-processing mutant-cell contain signal sequence-derived peptides. Nature (London) 356:443-446.
46. Yewdell, J. W., and J. R. Bennink. 1989. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxk T lymphocytes. Science 244: 1072-1075.
47. Zweerink, H. J., M. C. Gammon, U. Utz, S. Y. Sauma, T. Harrer, J. C. Hawkins, R. P. Johnson, A. Sirotina, J. D. Hermes, B. D. Walker, et al. 1993. Presentation of endogenous peptides to MHC class I-restricted cytoloxic T lymphocytes in transport deletion mutant T2 cells. J. Immunol. 150:1763-1771.